Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597381 | 0.91 | ELANE (0.62) | ELANEPDE4BPDE4D | |
| SCHEMBL8047269 | 0.84 | RIPK1 (0.41) | ELANEPDE4BPDE4DRIPK1MAPK14 | |
| SCHEMBL597097 | 0.82 | ELANE (0.52) | ELANEPDE4BPDE4D | |
| SCHEMBL596968 | 0.81 | ELANE (0.51) | ELANEPDE4BPDE4DPDE4APDE4C | |
| SCHEMBL525061 | 0.80 | ELANE (0.74) | ELANE | |
| SCHEMBL524078 | 0.78 | ELANE (0.64) | ELANE | |
| SCHEMBL597440 | 0.78 | ELANE (0.63) | ELANE | |
| SCHEMBL597096 | 0.77 | ELANE (0.61) | ELANE | |
| SCHEMBL14922192 | 0.77 | ELANE (0.61) | ELANE | |
| SCHEMBL2695330 | 0.77 | ELANE (0.65) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280048-A1 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRAZENECA R&D (SE) | 2010-11-04 | — | — | US | claimed |
| EP-2217591-A1 | SOME 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | claimed |
| WO-2009061271-A1 | SOME 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | WO | claimed |
| US-8466284-B2 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRA ZENECA AB (SE) | 2013-06-18 | — | — | US | disclosed |
| US-8466284-B2 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRA ZENECA AB (SE) | 2013-06-18 | — | — | US | disclosed |
| US-8466284-B2 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRA ZENECA AB (SE) | 2013-06-18 | — | — | US | disclosed |
| US-20100280048-A1 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRAZENECA R&D (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280048-A1 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRAZENECA R&D (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280048-A1 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRAZENECA R&D (SE) | 2010-11-04 | — | — | US | disclosed |
| EP-2217591-A1 | SOME 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061271-A1 | SOME 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280048-A1 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ELANE, SERPINB1, MPO | ELANE 1/4885PDE4B 576/4885PDE4D 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.